The Philips CPAP Recall: Degraded Foam, 15 Million Devices, and a $1.1 Billion Settlement

In June 2021, Philips Respironics recalled a large portion of its sleep and respiratory device line: continuous positive airway pressure (CPAP) machines used for sleep apnea, bi-level positive airway pressure (BiPAP) machines, and mechanical ventilators. The FDA has put the scope of the recall at roughly 15 million devices worldwide. The company's later settlement paperwork covered about 10.8 million of those sold in the United States between 2008 and 2021.

The defect was not in the electronics or the pressure delivery. It was in a piece of polyester-based polyurethane foam, called PE-PUR foam, that Philips used to dampen the sound and vibration of the motor. Over time, and especially in hot and humid conditions, that foam breaks down. When it degrades, black particles can enter the device's air pathway, and the foam can release chemical vapors known as volatile organic compounds. A CPAP or ventilator pushes that air directly into the user's airway. The people relying on these machines were, in the FDA's plain description, at risk of breathing in or swallowing pieces of degraded foam and the chemicals it gave off.

The FDA also warned that a common cleaning practice made the problem worse. Ozone-based cleaning machines, sold separately to sanitize CPAP equipment, appear to accelerate the foam breakdown. Many patients had been using them for years believing they were doing the responsible thing.

In July 2021, the FDA designated the recall as Class I. That is the agency's most serious category, reserved for situations where use of the device could cause serious injury or death. It is worth pausing on that label, because our other device articles involve a less severe classification and the contrast is instructive.

The Mazor X spine robot recalls we cover in our article on Mazor X surgical robot malfunctions were Class 2 recalls, the category for defects that can cause temporary or reversible harm, or where serious harm is possible but less likely. The Philips recall sits a full step above that on the FDA's scale. A Class I designation is the agency signaling that the risk is not theoretical and not minor.

A recall classification is not a finding that any particular patient was hurt. It is a statement about the seriousness of the known failure mode. For an individual patient, the questions are narrower: did you use a recalled device, for how long, and can your injury be connected to the exposure. Those are records-and-medicine questions, the same kind that decide every device case.

Device litigation is easy to caricature, so it is worth being precise about what the evidence establishes. The recall is settled fact. The health consequences of the foam exposure are more contested, and an honest article has to say so.

Philips commissioned its own testing and argued that the degraded foam was unlikely to result in appreciable harm to health. The FDA did not accept that. In its published foam testing summary, the agency said it did not believe the testing and analysis Philips had shared were adequate to fully evaluate the risks posed to users, and it ordered Philips to perform additional independent testing of the particulates and volatile organic compounds coming off the foam. The FDA maintained its warnings about the potential health risks while that testing went forward.

Patients and lawsuits have alleged a range of harms from the exposure, including respiratory problems and various cancers. Those causation questions are exactly the kind that get fought case by case, with expert testimony about the specific patient, the specific device, and the specific exposure. The existence of a Class I recall does not prove that a given patient's cancer came from the foam. What it does is establish that a widely used device had a documented, serious defect, which is the foundation a defective-device claim is built on.

The recall was not the end of the government's involvement. On April 9, 2024, a federal court entered a consent decree against Philips Respironics, filed by the Department of Justice on behalf of the FDA. A consent decree is a court-enforced agreement, and this one was severe.

It barred Philips, subject to narrow exceptions for medically necessary devices, from manufacturing and distributing sleep and respiratory devices at or from its facilities in Pennsylvania, and from resuming that work at a facility in Carlsbad, California, until the company met a list of conditions the FDA imposed. It also required Philips to carry out a recall remediation plan agreed with the FDA, under which affected patients would receive a new or reworked device or, for some devices, the option of a partial refund. A manufacturer being ordered by a federal court to stop making a product until it fixes its compliance is a rare and serious step.

The lawsuits were consolidated into a multidistrict litigation, MDL 3014, in the United States District Court for the Western District of Pennsylvania before Judge Joy Flowers Conti. Multidistrict litigation gathers thousands of similar federal cases before one judge for coordinated pretrial handling, which is the standard mechanism for large device and drug cases.

The cases resolved in a set of separate settlements. First, an economic loss settlement, prefunded with $479 million, resolved claims for the money patients lost because of the recall itself: the cost of replacing a device they could no longer safely use. It received final court approval on April 25, 2024. That settlement compensated the recall, not any physical injury.

Then, on April 29, 2024, Philips announced a settlement of the personal injury and medical monitoring claims in the United States for $1.1 billion, allocating $1.075 billion to personal injury claims and $25 million to medical monitoring. The medical monitoring settlement received final approval on December 5, 2024. Philips did not admit fault or liability, and did not concede that its devices caused any injury. That is standard language in a settlement of this size and does not change the fact that the money was paid.

For a reader, the practical takeaway is that the major class settlements are largely complete, with registration deadlines that in most cases have already passed. That is precisely why anyone who thinks they were injured by a recalled Philips device should not sit on the question, which we return to below.

A defective-device case like this one is a products liability claim, and it runs on a different track from an ordinary medical malpractice case. The target is the company that designed, made, and sold the product, not the doctor who prescribed it. A manufacturer can be held responsible when a design defect, a manufacturing defect, or a failure to warn made the product unreasonably dangerous and caused harm, regardless of whether the prescribing physician did anything wrong.

That is the thread connecting the Philips recall to the rest of our defective-device work. In our article on Mazor X surgical robot malfunctions, the defect is software that can display the wrong position of a surgical instrument, so a surgeon operates in the wrong place trusting a screen. In our article on the Medtronic HVAD heart pump recall, the defect is a life-sustaining implant that can fail to restart or weld shut. The Philips foam is a third version of the same problem: a device a patient was told to trust, carrying a hidden defect the patient had no way to detect. All three live in our Defective Medical Devices practice area, and all three turn on the same evidence, which is the manufacturer's own records of what it knew and when.

One more path matters for our practice. Many of these CPAP, BiPAP, and ventilator machines were prescribed to veterans and dispensed through the VA. A product claim against Philips is separate from any claim involving VA care, but if VA providers kept issuing or servicing recalled devices after the recall was public, that raises distinct questions under the Federal Tort Claims Act, which we cover in our FTCA article. We handle device and FTCA matters nationwide, not only in our home region.

Whether a defective-device claim can be built comes down to proof, and the proof is specific. For a recalled Philips device, that means identifying the exact machine: its model and serial number, when it was purchased or issued, and how long it was used. It means the medical records that document the alleged injury and its timeline. And it means, wherever possible, preserving the device itself rather than returning it, because the physical machine and its foam are evidence.

This is the same discipline every device case demands. The recall notice tells you a category of device was defective. It does not tell you that your device, in your use, caused your injury. Closing that gap is the work, and it depends on records that are easier to gather early than late.

If you used a recalled Philips CPAP, BiPAP, or ventilator and later developed a serious respiratory illness or cancer, the honest answer about your options is that it depends on your specific facts. The large class settlements have mostly closed their registration windows. Whether any avenue remains for you depends on when you were injured, when you knew or should have known the device might be the cause, whether you opted out of a settlement, and the statute of limitations that applies where you live.

That last point is the one that quietly ends cases. Product liability and personal injury claims have firm deadlines, and in many states the clock starts when you knew or reasonably should have known of the injury and its likely cause, not when you get around to asking a lawyer. Our article on the statute of limitations for medical malpractice explains how those deadlines and discovery rules work in DC, Maryland, and Virginia, and the same logic governs device claims.

The clock is already running, and it does not wait for you to feel certain. You do not need to know whether your machine was the specific problem before you ask. That is what a free case review is for. Peter Anderson reviews device inquiries personally. The right time to ask whether anything can still be done is while the answer can still help you, not after a deadline has passed in silence.